|
Comments
|
Today's Top SOA Links
From the Wires
Endologix to Report Second Quarter 2009 Financial Results on July 22, 2009
By: PR Newswire
Jul. 9, 2009 04:15 PM
Endologix will hold a conference call on After the live Web cast, the call will remain available on Endologix's Web site, www.endologix.com, through About Endologix Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.
COMPANY CONTACT: INVESTOR CONTACTS:
Endologix, Inc. The Ruth Group
John McDermott, CEO Nick Laudico (646) 536-7030
(949) 595-7200 Zack Kubow (646) 536-7020
www.endologix.com
SOURCE Endologix, Inc.
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
|
SYS-CON Featured Whitepapers
Most Read This Week |
|||||||||||||||||||||||||||